Tesofensine is a small-molecule monoamine-reuptake inhibitor used in neuroscience and metabolic research models. The original overview of this page asks three questions: monoamine-transporter research context, separating central and metabolic endpoints, and small-molecule purity and formulation checks. It is a small molecule, not a peptide.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.
Monoamine-transporter research context
Astrup and colleagues identified tesofensine as an inhibitor of the presynaptic uptake of noradrenaline, dopamine, and serotonin, and they assessed it in a phase II, randomised, double-blind, placebo-controlled trial in five Danish obesity-management centres (Astrup et al., 2008). After a two-week run-in, 203 patients with obesity (BMI 30–40 kg/m2) were prescribed an energy-restricted diet and assigned to tesofensine or placebo once daily for 24 weeks; the primary outcome was percentage change in bodyweight, analysed by modified intention to treat (NCT00394667) (Astrup et al., 2008). That paragraph is an identity and trial-design note. The dose arms reported in the paper are part of that published design; they are not a use instruction on this page.
Separating central and metabolic endpoints
The authors reported that 161 (79%) participants completed the study. After 24 weeks, diet and placebo produced a mean weight loss of 2.0% (SE 0.60). Tesofensine 0.25 mg, 0.5 mg, and 1.0 mg plus diet induced a mean weight loss of 4.5% (0.87), 9.2% (0.91), and 10.6% (0.84), respectively, greater than diet and placebo (p<0.0001) (Astrup et al., 2008). The most common adverse events they attributed to tesofensine were dry mouth, nausea, constipation, hard stools, diarrhoea, and insomnia. After 24 weeks, they reported no significant increases in systolic or diastolic blood pressure versus placebo at 0.25 mg and 0.5 mg, and an increase in heart rate of 7.4 beats per minute in the 0.5 mg group (p=0.0001) (Astrup et al., 2008). Those figures are transcribed as the authors reported them. They are not a regimen, and they do not establish a later phase III result; the authors themselves stated that the findings needed confirmation in phase III trials.
Central adverse-event and heart-rate observations should be kept distinct from metabolic body-weight endpoints when the paper is cited. This draft does not add unverified neuroscience claims beyond the transporter identity given above.
Small-molecule purity and formulation checks
Tesofensine should be documented with methods suited to a small molecule, including identity, impurity profiling, and formulation records. A purity percentage copied from a peptide template is not a complete file. Third-Party Peptide Testing, Explained and lot traceability still apply as documentation practices.
Tesofensine was not found as a standalone published item in Velnacor’s current research-material catalog listing used for this draft. Use the product directory and the COA Library, then confirm whether a current SKU exists and which documents apply in the inquiry. For packing at supply scale, see wholesale peptides.
Body-weight percentages, adverse-event lists, and heart-rate observations are different endpoints in the same trial report. They should be cited separately, and they should not be rewritten as a general “metabolic” or “neuropsychiatric” product claim. The trial used an energy-restricted diet in all arms, including placebo; that design detail belongs with any citation of the weight-loss figures. Formulation and impurity records for a small-molecule lot are still required even when the identity is taken from a well-known International Nonproprietary Name.
Selected published literature
- Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9653):1906-1913. doi:10.1016/s0140-6736(08)61525-1. PubMed 18950853. Cited for transporter identity and attributed trial findings, not as a use instruction.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.